

Wei-Ming Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/610702/publications.pdf>

Version: 2024-02-01

27
papers

295
citations

1040056

9
h-index

996975

15
g-index

30
all docs

30
docs citations

30
times ranked

558
citing authors

#	ARTICLE	IF	CITATIONS
1	HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia. <i>Disease Markers</i> , 2022, 2022, 1-22.	1.3	7
2	Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China. <i>Haematologica</i> , 2022, 107, 1966-1970.	3.5	4
3	A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. <i>Leukemia</i> , 2021, 35, 119-129.	7.2	15
4	Development of pancytopenia in a patient with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 1219-1220.	5.0	12
5	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	31
6	Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services. <i>Frontiers in Psychiatry</i> , 2021, 12, 679932.	2.6	4
7	Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI. <i>Frontiers in Oncology</i> , 2021, 11, 739871.	2.8	7
8	Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells. <i>Frontiers in Oncology</i> , 2021, 11, 769730.	2.8	10
9	The Comparison of Dasatinib 70 Mg/Day to 100 Mg/Day in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Multicenter, Prospective, Randomized Controlled Study. <i>Blood</i> , 2021, 138, 3615-3615.	1.4	0
10	Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i> -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). <i>Blood</i> , 2021, 138, 3598-3598.	1.4	9
11	EpsteinBarr virusencoded microRNAs involve in tumorigenesis and development. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 300-308.	0.1	1
12	Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e43-e49.	0.4	4
13	COVID-19 in persons with chronic myeloid leukaemia. <i>Leukemia</i> , 2020, 34, 1799-1804.	7.2	74
14	Epstein barr virus encodes miRNAs to assist host immune escape. <i>Journal of Cancer</i> , 2020, 11, 2091-2100.	2.5	18
15	Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. <i>Blood</i> , 2020, 136, 50-51.	1.4	18
16	Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia. <i>Current Medical Science</i> , 2019, 39, 217-221.	1.8	3
17	Monitoring of leukemia stem cells in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 2264-2266.	1.3	9
18	Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China. <i>Current Medical Science</i> , 2018, 38, 1005-1011.	1.8	3

#	ARTICLE	IF	CITATIONS
19	A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient. <i>Leukemia and Lymphoma</i> , 2016, 57, 2930-2933.	1.3	4
20	Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. <i>Leukemia Research</i> , 2016, 46, 61-68.	0.8	11
21	A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 58234-58243.	1.8	7
22	miR-125b regulates cell progression in chronic myeloid leukemia via targeting BAK1. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 447-59.	0.0	14
23	MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 955-67.	0.0	7
24	Comparison of outcomes of idarubicin intensified TBI+CY and traditional TBI+CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience. <i>Leukemia Research</i> , 2015, 39, 1192-1200.	0.8	13
25	Analysis of seizure risk factors after allogeneic hematopoietic stem cell transplantation: A 8 case report and literature review. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2013, 33, 656-660.	1.0	6
26	Gene and protein expression of proteinase-activated receptor-1, 2 in a murine model of acute graft vs host disease. <i>Frontiers of Medicine in China</i> , 2009, 3, 309-315.	0.1	0
27	Initial study on immune escape mechanism of mouse acute myelomonocytic leukemic cell line WEHI-3. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 291-293.	0.1	0